Protagonist Therapeutics, IncPTGX
| Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income (loss) | - | -37 | -39 | -77 | -66 | -126 | -127 | -79 | 275 |
|---|
| Stock-based compensation | 2 | 4 | 7 | 8 | 8 | 16 | 24 | 29 | 38 |
|---|
| Operating lease right-of-use asset amortization | - | - | - | - | - | 2 | 2 | 2 | 2 |
|---|
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|---|
| Accretion of discount on marketable securities | -0 | -1 | -0 | 1 | -0 | -2 | 1 | 5 | 9 |
|---|
| Other | - | - | - | - | - | - | - | 0 | - |
|---|
| Receivable from collaboration partner | - | 2 | 3 | 2 | -4 | -1 | -2 | 10 | 155 |
|---|
| Prepaid expenses and other assets | 2 | 0 | -1 | 3 | 1 | 3 | -4 | -2 | 4 |
|---|
| Research and development tax incentive receivable | - | -1 | 0 | -1 | 1 | 2 | -3 | - | - |
|---|
| Accounts payable | - | - | - | -3 | 0 | -1 | 2 | -3 | 1 |
|---|
| Payable to collaboration partner | - | - | 1 | 0 | 1 | -2 | -1 | -0 | -0 |
|---|
| Accrued expenses and other payables | 3 | 5 | 2 | 1 | 6 | 19 | -13 | -6 | 4 |
|---|
| Deferred revenue | - | - | -24 | 33 | -27 | -13 | -2 | - | 31 |
|---|
| Income taxes payable | - | - | - | - | - | - | - | - | 3 |
|---|
| Operating lease liability | - | - | - | - | - | 2 | 3 | 3 | 2 |
|---|
| Net cash provided by (used in) operating activities | - | 4 | -50 | -42 | -72 | -108 | -108 | -70 | 184 |
|---|
| Purchase of marketable securities | - | - | - | 167 | 280 | 287 | 215 | 191 | 622 |
|---|
| Proceeds from maturities of marketable securities | 14 | 56 | 74 | 114 | 190 | 272 | 307 | 152 | 324 |
|---|
| Purchases of property and equipment | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
|---|
| Net cash (used in) provided by investing activities | - | 16 | 2 | -54 | -91 | -16 | 91 | -39 | -299 |
|---|
| Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised | - | 1 | 1 | 2 | 3 | 6 | 4 | 5 | 26 |
|---|
| Tax withholding payments related to net settlement of restricted stock units | - | - | - | - | - | 0 | 0 | 1 | 1 |
|---|
| Proceeds from Issuance of Common Stock | - | - | 2 | 34 | 213 | 124 | - | 108 | - |
|---|
| Proceeds from Debt, Net of Issuance Costs | - | - | - | - | 42 | - | 15 | 24 | - |
|---|
| Proceeds from exercise of Warrants in exchange for issuance of Pre-Funded Warrants | - | - | - | - | - | - | - | 34 | - |
|---|
| Proceeds from Warrant Exercises | - | - | - | - | - | - | - | 1 | - |
|---|
| Issuance costs related to prior period common stock offering | - | - | - | - | - | - | 0 | - | - |
|---|
| Net cash provided by financing activities | - | 66 | 24 | 46 | 248 | 130 | 19 | 170 | 26 |
|---|
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | 0 | -0 | -0 | 0 | -0 | -0 | - | - |
|---|
| Net (decrease) increase in cash, cash equivalents and restricted cash | - | 85 | -24 | -49 | 84 | 6 | 2 | 61 | -89 |
|---|
| Cash paid for taxes | - | - | - | - | - | - | - | - | 2 |
|---|
| Right-of-use asset obtained in exchange for lease obligation | - | - | - | - | - | - | - | - | 11 |
|---|
| Leasehold Improvements Under Improvement Allowance | - | - | - | - | - | - | - | - | 1 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|